OA

Genascence to Present Full Data from Phase 1 Clinical Trial on GNSC-001, Company's Lead Program in Osteoarthritis, at European Society of Gene & Cell Therapy 30th Annual Congress

Retrieved on: 
Tuesday, October 24, 2023
MRI, VAS, CSO, Physical examination, AAV, Osteoarthritis, WOMAC, Clinical trial, Congress, OA, Infectious Diseases Society of America, PALO, Arthralgia, Pain, Inflammation, HIV disease progression rates, Society, Ice, Rest, DSM-IV codes, Disease, Cell, ESGCT, Blood, Disability, Safety, Vasopressin receptor 2, Office of Inspector General, U.S. Department of Health and Human Services, Synovial fluid, Patient, Pharmaceutical industry, Nursing, Vaccine

Study findings noted elevated IL-1Ra expression in synovial fluid and an encouraging trend in symptomatic improvement.

Key Points: 
  • Study findings noted elevated IL-1Ra expression in synovial fluid and an encouraging trend in symptomatic improvement.
  • These data will be delivered in a poster presentation at the European American Society of Gene & Cell Therapy's (ESGCT) 30th Annual Congress being held October 24-27, 2023, in Brussels, Belgium.
  • Clinical trial participants developed various degrees of anti-AAV neutralizing antibodies after injection of GNSC-001, but no capsid targeted T-cell response was detected.
  • The study was supported by funding from the U.S. Department of Defense Peer Reviewed Medical Research Program (PRMRP).

Wiley and German DEAL Consortium to Sign New 5-Year Agreement

Retrieved on: 
Thursday, October 19, 2023
Education, Communications, University, Publishing, Consensus, DEAL, Microsoft Access, NYSE, Freie Erde, OA, Research, Consensus decision-making, Senior, Growth, Consortium, Partnership, Librarian, Society, Library, Pharmaceutical industry, Renewable energy

Wiley (NYSE: WLY) today announced its intent to enter a new five-year agreement with the DEAL Consortium, a countrywide consortium representative of more than 1,000 academic institutions in Germany, commencing January 2024.

Key Points: 
  • Wiley (NYSE: WLY) today announced its intent to enter a new five-year agreement with the DEAL Consortium, a countrywide consortium representative of more than 1,000 academic institutions in Germany, commencing January 2024.
  • Wiley and DEAL are creating a blueprint for the next phase of open access publishing to better meet the evolving needs of the scholarly community.
  • Wiley was the first publisher to sign an agreement with DEAL, which makes this partnership the most robust and long-lasting in Germany.
  • Their new agreement will continue to provide authors at German institutions with open access publishing options across Wiley’s portfolio.

CCC Releases AI-Enabled Affiliation Matching Software Powering Open Access Publication Modeling and Analysis for Publishers

Retrieved on: 
Tuesday, October 10, 2023
Software, Research, Professional Services, Data Management, Technology, Artificial Intelligence, Publishing, Science, Legal, Communications, Other Technology, Other Science, Frankfurt Book Fair, Government, STM, AI, LLM, Book, OpenAI, Intelligence, Legislation, Workflow, Society, APC, Association of Learned and Professional Society Publishers, Publication, ChatGPT, Society for Scholarly Publishing, Open Access Scholarly Publishing Association, International Association, Open access, SSP, Learning, CCC, OA, OASPA, ALPSP

CCC , the leading provider of Open Access (OA) workflow solutions, announces new data import capabilities and AI-enabled affiliation matching in its OA Agreement Intelligence modeling and analytics tool that provides publishers with a 360-degree view of disambiguated publication data to build accurate, transparent institutional offers regarding OA.

Key Points: 
  • CCC , the leading provider of Open Access (OA) workflow solutions, announces new data import capabilities and AI-enabled affiliation matching in its OA Agreement Intelligence modeling and analytics tool that provides publishers with a 360-degree view of disambiguated publication data to build accurate, transparent institutional offers regarding OA.
  • OA Agreement Intelligence supports the import of publication data from subscriptions and non-RightsLink sources to further enhance the capability to analyze and compare various business scenarios.
  • The solution combines sophisticated, AI-enabled, affiliation-matching technology and analytic capabilities, to reliably disambiguate institution affiliation and funder relationships.
  • CCC is a member of OASPA (Open Access Scholarly Publishers Association), ALPSP (Association of Learned and Professional Society Publishers), STM (International Association of STM Publishers), and SSP (Society for Scholarly Publishing).

EBSCO Information Services Releases Serials Price Projection Report for 2024

Retrieved on: 
Wednesday, October 11, 2023
OA, Projection, EBSCO, Information services, Open access, EBSCO Information Services

IPSWICH, Mass., Oct. 11, 2023 /PRNewswire-PRWeb/ -- EBSCO Information Services (EBSCO) has published the 2024 Serials Price Projection Report. This year's report projects that the overall effective publisher price increases for academic and academic medical libraries are expected to be (before any currency impact) in the range of three to four percent for individual e-journal titles, two to three percent for e-journal packages and four to five percent for print titles.

Key Points: 
  • IPSWICH, Mass., Oct. 11, 2023 /PRNewswire-PRWeb/ -- EBSCO Information Services (EBSCO) has published the 2024 Serials Price Projection Report.
  • Published annually, EBSCO's Serials Price Projection is based on surveys of a wide range of publishers and reviews of historical serials pricing data to assist information professionals as they make budgeting decisions for the upcoming renewals season.
  • Published annually, EBSCO's Serials Price Projection is based on surveys of a wide range of publishers and reviews of historical serials pricing data to assist information professionals as they make budgeting decisions for the upcoming renewals season.
  • To read the 2024 Serials Price Projection Report in its entirety and view the Five-Year Journal Price Increase History, visit: https://www.ebsco.com/sites/default/files/acquiadam-assets/EBSCO-Serials...

U.S. FDA GRANTS LIPOGEMS® SECOND IDE APPROVAL FOR A CLINICAL TRIAL ON THE TREATMENT FOR KNEE OA

Retrieved on: 
Wednesday, October 4, 2023
Arthroscopy, Private practice, OA, Knee, Physician, IDE, FDA, Safety, Pharmaceutical industry

ATLANTA, Oct. 4, 2023 /PRNewswire/ -- The U. S. Food and Drug Administration (FDA) has awarded Lipogems another Investigational Device Exemption (IDE) study for the use of MicroFat for the treatment of knee osteoarthritis (OA).

Key Points: 
  • ATLANTA, Oct. 4, 2023 /PRNewswire/ -- The U. S. Food and Drug Administration (FDA) has awarded Lipogems another Investigational Device Exemption (IDE) study for the use of MicroFat for the treatment of knee osteoarthritis (OA).
  • The second IDE Study will be conducted for the safety and efficacy for the treatment of knee OA compared to saline and will include 15-20 well-respected academic and private practice orthopaedic institutions.
  • Lipogems has worked closely with the FDA to seek a separate FDA clearance for a specific indication in knee OA and while Lipogems pursues the Knee OA indication physicians may continue to use the product for the general indications specified in the existing FDA clearance.
  • We pursued this specific indication because over 40+ independent peer-reviewed publications with up to 5 years follow up showed extremely positive results using MicroFat for Knee OA."

U.S. FDA GRANTS LIPOGEMS® SECOND IDE APPROVAL FOR A CLINICAL TRIAL ON THE TREATMENT FOR KNEE OA

Retrieved on: 
Wednesday, October 4, 2023
Arthroscopy, Private practice, OA, Knee, Physician, IDE, FDA, Safety, Pharmaceutical industry

ATLANTA, Oct. 4, 2023 /PRNewswire/ -- The U. S. Food and Drug Administration (FDA) has awarded Lipogems another Investigational Device Exemption (IDE) study for the use of MicroFat for the treatment of knee osteoarthritis (OA).

Key Points: 
  • ATLANTA, Oct. 4, 2023 /PRNewswire/ -- The U. S. Food and Drug Administration (FDA) has awarded Lipogems another Investigational Device Exemption (IDE) study for the use of MicroFat for the treatment of knee osteoarthritis (OA).
  • The second IDE Study will be conducted for the safety and efficacy for the treatment of knee OA compared to saline and will include 15-20 well-respected academic and private practice orthopaedic institutions.
  • Lipogems has worked closely with the FDA to seek a separate FDA clearance for a specific indication in knee OA and while Lipogems pursues the Knee OA indication physicians may continue to use the product for the general indications specified in the existing FDA clearance.
  • We pursued this specific indication because over 40+ independent peer-reviewed publications with up to 5 years follow up showed extremely positive results using MicroFat for Knee OA."

Opportunity Austin names Ed Latson as first chief executive officer

Retrieved on: 
Thursday, September 21, 2023
Latson, Partnership, Austin Community College District, Bachelor of Arts, University of Texas at Austin, Quality of life, History, ARMA, Organization, OA, Philosophy, University, Locke Lord, Economic development, Management, Central Texas, United Way

AUSTIN, Texas, Sept. 21, 2023 /PRNewswire/ -- Today, Opportunity Austin—the economic development organization aimed at fostering job-creating investment in the five-county Central Texas region—announced Ed Latson, currently chief executive officer of The Austin Regional Manufacturers Association, as the organization's first full-time CEO. The hiring is effective October 21.

Key Points: 
  • AUSTIN, Texas, Sept. 21, 2023 /PRNewswire/ -- Today, Opportunity Austin —the economic development organization aimed at fostering job-creating investment in the five-county Central Texas region—announced Ed Latson, currently chief executive officer of The Austin Regional Manufacturers Association, as the organization's first full-time CEO.
  • Caldwell County Judge Hoppy Haden - "Selecting Ed Latson as Opportunity Austin's first CEO is an exciting moment for the organization.
  • I look forward to another exceptional and productive partnership with Opportunity Austin and Ed Latson as their leader."
  • We are confident that Ed will bring the passion, strategic thinking and vision that will be critical to guiding Opportunity Austin through this next chapter."

Fujitsu pioneering supply chain CO2 visualization with successful participation in WBCSD PACT Implementation program

Retrieved on: 
Wednesday, September 13, 2023
Carbon, Pocs, Desloge Consolidated Lead Company, General assembly, Partnership, Assembly, World Business Council for Sustainable Development, PCF, Pathfinder network, Data collection, The Climate Group, SABIC, City, WBCSD, Specialization, Visualization, ESG, JEITA, Sustainable development, Summit, CO2, Sales, Renewable energy, EU, Materiality, PACT, OA, Fujitsu

Fujitsu also identified solutions to real supply chain issues, including how to improve supplier engagement and build ecosystems through PCF data exchange using actual supplier data.

Key Points: 
  • Fujitsu also identified solutions to real supply chain issues, including how to improve supplier engagement and build ecosystems through PCF data exchange using actual supplier data.
  • In addition to this project, Fujitsu will also provide the know-how gained through data linkage and methodology standardization as ESG management platform services and digital supply chain services for its Fujitsu Uvance portfolio.
  • To achieve carbon neutrality, reducing CO2 emissions not only by one company but also by the entire supply chain is a global challenge.
  • As a Tier2 supplier, he is responsible for acquiring partners, collecting data from the supply chain, and collaborating with them.

Advantive Announces Growth Recapitalization

Retrieved on: 
Wednesday, September 13, 2023
Technology, Software, Partnership, MES, Statistical process control, TA, Manufacturing execution system, ERP, Forecasting, OA, TA Associates, ST6, Insight Partners, SPC, Management, Aerospool WT10 Advantic

Advantive (“the Company”), a leading provider of mission-critical software for specialty manufacturing and distribution businesses, today announced a strategic growth recapitalization led by a group of investors that includes Insight Partners and OA Private Capital (“OAPC”).

Key Points: 
  • Advantive (“the Company”), a leading provider of mission-critical software for specialty manufacturing and distribution businesses, today announced a strategic growth recapitalization led by a group of investors that includes Insight Partners and OA Private Capital (“OAPC”).
  • Advantive was formed in 2022 by TA Associates (“TA”), a leading global private equity firm, and ST6, an experienced team of software operating executives.
  • TA remains the largest shareholder of Advantive and is also reinvesting in the Company as part of the recapitalization.
  • “We are very proud of what the Advantive team has accomplished in the last two years against an exceedingly challenging operating environment,” said Mark Friedman, Executive Chairman of Advantive and Managing Director at ST6.

Frontiers Adopts CCC Ringgold Identify Database as its PID Solution

Retrieved on: 
Tuesday, September 12, 2023
Research, Legal, Technology, Publishing, Security, Communications, Professional Services, Software, Data Management, Science, Metadata, Database, Frontiers, ISO, Article processing charge, ISNI, Open access, ID, APC, CCC, Organization, OA, Acquisition, Pids, PID, Scientific community, Knowledge, Ecosystem, Copyright Clearance Center, Cryptocurrency, Management

CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, today announced Gold Open Access (OA) publisher Frontiers has adopted the industry-leading Ringgold Identify Database as its Persistent Identifier (PID) solution to help power its OA models by normalizing and disambiguating organization data.

Key Points: 
  • CCC , a leader in advancing copyright, accelerating knowledge, and powering innovation, today announced Gold Open Access (OA) publisher Frontiers has adopted the industry-leading Ringgold Identify Database as its Persistent Identifier (PID) solution to help power its OA models by normalizing and disambiguating organization data.
  • With over 600,000 Ringgold PIDs and metadata records, the Ringgold Identify Database provides a curated view of organization data to help stakeholders improve data quality, drive strategic decision-making, and support data interoperability across the scholarly communications ecosystem.
  • Used by intermediaries, funders, institutions, and a growing list of leading publishers, the Ringgold Identify Database is the only solution to offer structured organizational hierarchies and consortia connections to help stakeholders quickly understand complex relationships.
  • The Ringgold Identify Database includes rich metadata and additional identifiers, including the ISNI ID, an open ISO standard to support wider interoperability.